Ferric derisomaltose versus usual care in patients with heart failure, reduced ejection fraction, and iron deficiency: a short-term UK cost-utility analysis based on the IRONMAN RCT

被引：0
|
作者：
Pollock, R. [1 ]
Kalra, P. R. [2 ]
Mcmurray, J. J., V [3 ]
Graham, F. J. [4 ]
Pellicori, P. [5 ]
Cleland, J. G. F. [5 ]
Ford, I [4 ]
机构：
[1] Covalence Res Ltd, Harpenden, England
[2] Portsmouth Hosp Univ NHS Trust, Dept Cardiol, Portsmouth, England
[3] BHF Glasgow Cardiovasc Res Ctr, Sch Cardiovasc & Metab Hlth, Glasgow, Scotland
[4] Robertson Ctr Biostat, Glasgow, Scotland
[5] Univ Glasgow, Sch Cardiovasc & Metab Hlth, Glasgow, Scotland
来源：
EUROPEAN HEART JOURNAL | 2024年 / 45卷
关键词：
D O I：
10.1093/eurheartj/ehae666.852
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The Impact of Ferric Derisomaltose on Cardiovascular and Noncardiovascular Events in Patients With Anemia, Iron De ficiency, and Heart Failure With Reduced Ejection Fraction
    Ray, Robin
    Ford, Ian
    Cleland, John G. F.
    Graham, Fraser
    Ahmed, Fozia Z.
    Al-Mohammad, Abdallah
    Cowburn, Peter J.
    Critoph, Chris
    Kalra, Philip A.
    Lane, Rebecca E.
    Ludman, Andrew
    Pellicori, Pierpaolo
    Petrie, Mark C.
    Robertson, Michelle
    Seed, Alison
    Squire, Iain
    Kalra, Paul R.
    JOURNAL OF CARDIAC FAILURE, 2024, 30 (05) : 682 - 690
  • [22] Cost-utility analysis of add-on dapagliflozin in heart failure with preserved or mildly reduced ejection fraction
    Tang, Yi
    Sang, Haiqiang
    ESC HEART FAILURE, 2023, 10 (04): : 2524 - 2533
  • [23] Cost-Utility Analysis of Sacubitril/Valsartan Use Compared With Standard Care in Chronic Heart Failure Patients With Reduced Ejection Fraction in South Korea
    Park, Sun-Kyeong
    Hong, Sung-Hyun
    Kim, HyoJin
    Kim, Sungju
    Lee, Eui-Kyung
    CLINICAL THERAPEUTICS, 2019, 41 (06) : 1066 - 1079
  • [24] Cost-utility analysis of add-on vericiguat for the treatment of chronic heart failure with reduced ejection fraction in China
    Wang, Lu
    Huo, Xuechen
    Sun, Haiyan
    Liu, Feiyu
    Huang, Ruiqin
    Zhao, Quan
    BMC PUBLIC HEALTH, 2024, 24 (01)
  • [25] Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction
    Rungroj Krittayaphong
    Unchalee Permsuwan
    American Journal of Cardiovascular Drugs, 2022, 22 : 577 - 590
  • [26] Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction
    Krittayaphong, Rungroj
    Permsuwan, Unchalee
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2022, 22 (05) : 577 - 590
  • [27] Cost-utility analysis and eligibility of dapagliflozin for patients with heart failure across the whole spectrum of ejection fraction
    Kim, E. S.
    Park, S. K.
    Youn, J. C.
    Lee, H. Y.
    Kim, M. S.
    Choi, J. O.
    Kang, S. M.
    Yoo, B. S.
    Choi, D. J.
    Oh, B. H.
    Baek, S. H.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 197 - 197
  • [28] Cost-utility analysis of add-on Qili Qiangxin capsules in chronic heart failure with reduced ejection fraction in China
    Wang, Lu
    Wang, Yinglin
    Zhao, Quan
    ESC HEART FAILURE, 2025,
  • [29] Cost-utility of ferric carboxymaltose (Ferinject®) for iron-deficiency anemia patients with chronic heart failure in South Korea
    Eun-A Lim
    Hyun-Soon Sohn
    Haeyoung Lee
    Sang-Eun Choi
    Cost Effectiveness and Resource Allocation, 12
  • [30] Cost-utility of ferric carboxymaltose (Ferinject®) for iron-deficiency anemia patients with chronic heart failure in South Korea
    Lim, Eun-A
    Sohn, Hyun-Soon
    Lee, Haeyoung
    Choi, Sang-Eun
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2014, 12
12345